What We're Reading: CRISPR Coronavirus Tests; New PDUFA Date for BMS CAR T Therapy; Teams Design Cheap Ventilators
Investigators hope that an experimental test could detect the novel coronavirus at a much lower cost than current tests; the FDA has extended the action date for a chimeric antigen receptor (CAR) T-cell therapy application from Bristol Myers Squibb (BMS); engineering teams devise inexpensive ventilators for emergency use.
Experimental Prototype Uses CRISPR Technology to Test for Coronavirus
A team of researchers has produced an experimental prototype of a test to diagnose the novel coronavirus that causes coronavirus disease 2019 (COVID-19) using CRISPR gene-editing technology,
FDA Extends Action Date for BMS’ CAR T-Cell Therapy by 3 Months
After Bristol Myers Squibb (BMS) submitted additional information to supplement its biologics license application for lisocabtagene maraleucel (liso-cel), the FDA has extended the Prescription Drug User Fee Act date by 3 months to November 16, 2020. The extension was
Teams Devise Low-Cost Ventilators, Aiming to Boost Global Supply
Engineering departments at universities nationwide are teaming up to design low-cost emergency ventilators after the COVID-19 pandemic has uncovered shortages in the supply chain,
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- Duchenne Action Month 2025: Looking Back at News and Expert Insights
September 14th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025